The Covid ef­fect has trig­gered some rad­i­cal changes to the top 50 bio­phar­ma list, bring­ing a whole new group of play­ers in­to the big league

Back on March 11 last year, the bio­phar­ma world was go­ing in­to a glob­al lock­down. The pan­dem­ic was of­fi­cial­ly hit­ting the US, and a broad fear had set­tled in on the re­al­iza­tion that this time around, af­ter years of pan­dem­ic fears, we were re­al­ly in for it. Wall Street shiv­ered in fear.

Then the up­side be­came clear, and the Covid-19 ef­fect pro­ceed­ed to com­plete­ly re­vamp the list of top bio­phar­ma firms by mar­ket cap in re­mark­able ways.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER